Perspective Therapeutics’ (CATX) “Outperform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a research report released on Tuesday morning,Benzinga reports. Royal Bank of Canada currently has a $16.00 target price on the stock.

Several other equities analysts have also recently issued reports on CATX. Wedbush reissued an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research note on Monday. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $24.00 to $5.00 in a research report on Monday, November 25th. UBS Group assumed coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective for the company. Truist Financial started coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective for the company. Finally, Oppenheimer reduced their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.14.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $3.16 on Tuesday. The firm’s 50-day simple moving average is $4.45 and its 200 day simple moving average is $10.06. Perspective Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. As a group, equities analysts expect that Perspective Therapeutics will post -0.88 earnings per share for the current fiscal year.

Insider Buying and Selling at Perspective Therapeutics

In other Perspective Therapeutics news, CFO Jonathan Robert Hunt acquired 12,829 shares of the stock in a transaction dated Monday, November 25th. The stock was purchased at an average price of $3.82 per share, with a total value of $49,006.78. Following the transaction, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at $186,416. This trade represents a 35.66 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Heidi Henson bought 25,975 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were acquired at an average price of $3.85 per share, for a total transaction of $100,003.75. Following the completion of the purchase, the director now owns 25,975 shares in the company, valued at $100,003.75. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 67,570 shares of company stock worth $256,789 over the last quarter. Insiders own 3.52% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CATX. Trueblood Wealth Management LLC lifted its holdings in shares of Perspective Therapeutics by 37.0% in the 4th quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company’s stock valued at $71,000 after buying an additional 6,000 shares during the period. Taylor & Morgan Wealth Management LLC grew its stake in Perspective Therapeutics by 86.7% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 56,000 shares of the company’s stock valued at $179,000 after acquiring an additional 26,000 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Perspective Therapeutics by 24.1% in the third quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company’s stock valued at $333,000 after purchasing an additional 4,844 shares during the last quarter. Barclays PLC grew its holdings in shares of Perspective Therapeutics by 587.9% in the third quarter. Barclays PLC now owns 114,075 shares of the company’s stock valued at $1,523,000 after purchasing an additional 97,493 shares during the period. Finally, Geode Capital Management LLC increased its stake in Perspective Therapeutics by 12.5% during the third quarter. Geode Capital Management LLC now owns 1,164,204 shares of the company’s stock worth $15,546,000 after acquiring an additional 129,654 shares during the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.